Division

Resources for Researchers

NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.

The National Emerging Infectious Diseases Laboratories (NEIDL) is part of a national network of secure facilities studying infectious diseases that are—or have the potential to become—major public health concerns

The George Mason University National Center for Biodefense and Infectious Diseases Biomedical Research Laboratory (BRL) is one of the NIAID-supported Biocontainment Laboratories. The RBL supports research programs in the National Center for Biodefense and Infectious Diseases focusing on host resp

The Rutgers University Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories. The RBL is a highly secure facility designed to provide an ultra-safe work environment for scientists and support staff, as well as the public at large.

The University of Chicago Howard T. Ricketts Laboratory (HTRL) is one of the NIAID-supported Biocontainment Laboratories. The HTRL is a state of the art BSL-3 facility constructed to support research on bacterial and viral pathogens.

As one of two National Biocontainment Laboratories constructed under grants awarded by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), the Galveston National Laboratory (GNL) enables progress in our understanding of the fundamental mechanisms u

Provides services to facilitate preclinical development of materials that are derived from biotechnology processes. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.

This contract provides gap-filling support services for HIV prevention drug developers including academic (investigators), for-profit and not-for-profit small and large companies, and other product innovators (henceforth identified as Sponsors) for the development of HIV non-vaccine biomedical pr

This service provides follow-up studies of products which already have been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development of the product as an HIV therapeutic.

This service provides evaluation of products in animal efficacy models. A product must demonstrate a potent and selective activity profile in vitro against the HIV strain used in the model prior to its acceptance as a candidate for this service.

This service program supports the development and manufacture, of a wide variety of pharmaceutical dosage formulations, including tablets, capsules, semi-solid preparations, injectibles, and sustained-release products. If requested, manufacturing can be done under GMP.

This service provides chemical synthesis of lead compounds for use in additional drug development studies. Compounds must previously have been successfully synthesized to be candidates for this service. Synthesis of new analogs is not supported.

The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical speci

The Interventional Agent Development Services program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious disease-causing pathogens and/or toxins.